Acadia's DAYBU® Nears EU Approval for Rett Syndrome Treatment
Event summary
- CHMP recommends approval of DAYBU® for neurobehavioral symptoms of Rett syndrome in the EU.
- European Commission expected to issue final decision in coming months.
- DAYBU® would be the first therapy approved for this indication in the EU if authorized.
- Recommendation based on Phase 3 LAVENDER™ study showing statistically significant improvements.
The big picture
Acadia's potential approval of DAYBU® in the EU marks a strategic milestone in addressing a critical gap in Rett syndrome treatment. The positive CHMP opinion underscores the growing focus on neurodevelopmental disorders and the increasing demand for targeted therapies in rare disease markets. With no prior approved treatments for neurobehavioral symptoms of Rett syndrome in the EU, DAYBU®'s approval could set a precedent for future therapeutic developments in this space.
What we're watching
- Regulatory Timing
- The pace at which the European Commission issues its final decision will determine DAYBU®'s market entry timeline.
- Market Penetration
- Whether Acadia can effectively address the significant unmet need in the EU Rett syndrome community.
- Commercial Strategy
- How Acadia plans to position DAYBU® alongside its existing portfolio in neurological and rare disease treatments.
Related topics